• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环中晚期糖基化终产物可溶性受体与慢性肾脏病患者的动脉粥样硬化呈负相关。

Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.

机构信息

CNR Institute of Clinical Physiology, Pisa, Italy.

出版信息

Kidney Int. 2010 Feb;77(3):225-31. doi: 10.1038/ki.2009.419. Epub 2009 Nov 18.

DOI:10.1038/ki.2009.419
PMID:19924100
Abstract

The soluble receptor of advanced glycation end product (sRAGE) prevents vascular damage in experimental animal models, and observational studies in the general population support the hypothesis that sRAGE may exert a protective role on the vasculature. To test this in patients with chronic kidney disease, we determined the relationship between plasma sRAGE and carotid atherosclerosis in 142 patients with an average estimated glomerular filtration rate (eGFR) of 32 ml/min per 1.73 m(2) and 49 healthy control individuals matched for age and gender. Plasma sRAGE was significantly higher in patients with chronic kidney disease than in the control cohort. In an aggregate analysis of the patients and controls, there was a significant inverse relationship between eGFR and sRAGE, with a breakpoint in the regression line at 64 ml/min per 1.73 m(2). Significant inverse relationships were found for sRAGE to intima-media thickness and plaque number in the patients with chronic kidney disease, but no such associations were found in the controls. On covariance analysis, the slopes of intima-media thickness and plaque number to sRAGE were significantly steeper in patients with chronic kidney disease than in the controls. Furthermore, a significant interaction was found between sRAGE and smoking for predicting atherosclerotic plaques in patients with chronic kidney disease. The pathophysiological significance of this correlation will have to await more mechanistic studies.

摘要

可溶性晚期糖基化终产物受体(sRAGE)可预防实验动物模型中的血管损伤,而一般人群的观察性研究支持 sRAGE 可能对血管发挥保护作用的假说。为了在慢性肾脏病患者中验证这一点,我们在 142 名平均估算肾小球滤过率(eGFR)为 32ml/min/1.73m²的患者和 49 名年龄和性别匹配的健康对照者中,测定了血浆 sRAGE 与颈动脉粥样硬化之间的关系。与对照组相比,慢性肾脏病患者的血浆 sRAGE 明显升高。在患者和对照组的综合分析中,eGFR 与 sRAGE 之间存在显著的负相关关系,在 64ml/min/1.73m² 处回归线出现拐点。在慢性肾脏病患者中,sRAGE 与内膜-中层厚度和斑块数量之间存在显著的负相关关系,但在对照组中未发现这种相关性。在协方差分析中,慢性肾脏病患者的内膜-中层厚度和斑块数量与 sRAGE 的斜率明显比对照组陡峭。此外,在慢性肾脏病患者中,sRAGE 与吸烟之间存在显著的交互作用,可预测动脉粥样斑块。这种相关性的病理生理意义尚需更多的机制研究来证实。

相似文献

1
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.循环中晚期糖基化终产物可溶性受体与慢性肾脏病患者的动脉粥样硬化呈负相关。
Kidney Int. 2010 Feb;77(3):225-31. doi: 10.1038/ki.2009.419. Epub 2009 Nov 18.
2
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).循环晚期糖基化终产物可溶性受体(sRAGE)与慢性肾脏病(CKD)患者左心室肥厚。
Nutr Metab Cardiovasc Dis. 2012 Sep;22(9):748-55. doi: 10.1016/j.numecd.2010.11.008. Epub 2011 Apr 5.
3
Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.血浆中可溶性晚期糖基化终产物受体(sRAGE)和 RAGE 的促炎配体(EN-RAGE)水平与腹膜透析患者的颈动脉粥样硬化有关。
Atherosclerosis. 2012 Jan;220(1):208-14. doi: 10.1016/j.atherosclerosis.2011.07.115. Epub 2011 Aug 5.
4
Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.血清晚期糖基化终产物可溶性受体水平与早期类风湿关节炎患者的主动脉增强指数——一项前瞻性研究。
Semin Arthritis Rheum. 2013 Feb;42(4):333-45. doi: 10.1016/j.semarthrit.2012.07.002. Epub 2012 Aug 22.
5
Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.可溶性晚期糖基化终末产物受体(sRAGE)、内源性晚期糖基化终末产物受体(esRAGE)水平与血管炎症的关系:(18)F-氟脱氧葡萄糖正电子发射断层扫描分析。
Atherosclerosis. 2012 Feb;220(2):402-6. doi: 10.1016/j.atherosclerosis.2011.11.008. Epub 2011 Nov 16.
6
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.晚期糖基化终末产物可溶性受体血浆水平与肾脏疾病风险的关联:社区动脉粥样硬化风险研究
Nephrol Dial Transplant. 2015 Jan;30(1):77-83. doi: 10.1093/ndt/gfu282. Epub 2014 Aug 21.
7
High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.可溶性晚期糖基化终产物受体在有症状颈动脉粥样硬化患者中的高血浆水平。
Eur J Clin Invest. 2009 Dec;39(12):1065-72. doi: 10.1111/j.1365-2362.2009.02212.x. Epub 2009 Oct 7.
8
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.非糖尿病慢性肾病患者血清晚期糖基化终产物和高迁移率族蛋白B1水平与不对称二甲基精氨酸的正相关关系。
Metabolism. 2009 Nov;58(11):1624-8. doi: 10.1016/j.metabol.2009.05.018. Epub 2009 Jul 15.
9
Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects.在无症状受试者中,循环晚期糖基化终末产物可溶性受体与氧化型低密度脂蛋白呈负相关。
J Int Med Res. 2012;40(5):1878-83. doi: 10.1177/030006051204000527.
10
Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.晚期糖基化终末产物受体——慢性血液透析患者的可溶性形式及基因多态性
Nephrol Dial Transplant. 2007 Jul;22(7):2020-6. doi: 10.1093/ndt/gfm050. Epub 2007 Mar 8.

引用本文的文献

1
Decoy receptors as biomarkers for exploring aetiology and designing new therapies.诱饵受体作为探索病因和设计新疗法的生物标志物。
Clin Kidney J. 2024 Jul 18;17(8):sfae222. doi: 10.1093/ckj/sfae222. eCollection 2024 Aug.
2
Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome.通过整合多组学蛋白质组学和转录组学,鉴定慢性肾脏病和肾功能的新治疗靶点。
Genome Med. 2024 Jun 19;16(1):84. doi: 10.1186/s13073-024-01356-x.
3
The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.
晚期糖基化终末产物-晚期糖基化终末产物受体轴与慢性阻塞性肺疾病的多病共存病理生理学
J Clin Med. 2023 May 9;12(10):3366. doi: 10.3390/jcm12103366.
4
RAGE pathway activation and function in chronic kidney disease and COVID-19.晚期糖基化终末产物受体(RAGE)通路在慢性肾脏病和2019冠状病毒病(COVID-19)中的激活与功能
Front Med (Lausanne). 2022 Aug 9;9:970423. doi: 10.3389/fmed.2022.970423. eCollection 2022.
5
Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?晚期糖基化终产物(AGEs)与慢性肾脏病:现代饮食是否会使肾脏老化?
Nutrients. 2022 Jun 28;14(13):2675. doi: 10.3390/nu14132675.
6
The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.晚期糖基化终产物及其可溶性受体在肾脏疾病中的作用。
Int J Mol Sci. 2022 Mar 22;23(7):3439. doi: 10.3390/ijms23073439.
7
Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression.晚期糖基化终末产物(AGEs)及其受体(RAGE)对癌症代谢信号通路及其进展的影响。
Glycoconj J. 2021 Dec;38(6):717-734. doi: 10.1007/s10719-021-10031-x. Epub 2022 Jan 22.
8
Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study.可溶性晚期糖基化终产物受体(sRAGE)与动脉粥样硬化风险社区研究参与者非酒精性脂肪性肝病(NAFLD)之间的关系。
Dig Liver Dis. 2021 Jul;53(7):873-878. doi: 10.1016/j.dld.2021.02.005. Epub 2021 Feb 24.
9
Advanced Glycation End Products (AGE) and Soluble Forms of AGE Receptor: Emerging Role as Mortality Risk Factors in CKD.晚期糖基化终末产物(AGE)与AGE受体的可溶性形式:在慢性肾脏病中作为死亡风险因素的新作用。
Biomedicines. 2020 Dec 21;8(12):638. doi: 10.3390/biomedicines8120638.
10
Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update.慢性肾脏病中的内皮功能障碍:从生物学机制到临床结局——2020年更新
J Clin Med. 2020 Jul 23;9(8):2359. doi: 10.3390/jcm9082359.